Literature DB >> 15538606

Charles Bonnet syndrome and visual acuity--the involvement of dynamic or acute sensory deprivation.

Yasuko Shiraishi1, Takeshi Terao, Kenji Ibi, Jun Nakamura, Akihiko Tawara.   

Abstract

A 61-year-old patient suffered from Charles Bonnet syndrome (CBS) while his visual acuity declined, whereas CBS subsided after he became blind. These findings suggest that reduction of visual acuity (dynamic or acute impairment) has a greater impact on the onset of CBS than low visual acuity (static or chronic impairment) per se in some patients. They may also explain why patients with low visual acuity do not always suffer from CBS. Although further studies are required, the present case highlights the importance of the differentiation between lowering and low visual acuity in the etiology of CBS.

Entities:  

Mesh:

Year:  2004        PMID: 15538606     DOI: 10.1007/s00406-004-0515-0

Source DB:  PubMed          Journal:  Eur Arch Psychiatry Clin Neurosci        ISSN: 0940-1334            Impact factor:   5.270


  16 in total

1.  Visual symptoms associated with choroidal neovascularization. Photopsias and the Charles Bonnet syndrome.

Authors:  G C Brown; R P Murphy
Journal:  Arch Ophthalmol       Date:  1992-09

Review 2.  The Charles Bonnet syndrome: a review.

Authors:  A Fernandez; G Lichtshein; W V Vieweg
Journal:  J Nerv Ment Dis       Date:  1997-03       Impact factor: 2.254

3.  The Charles Bonnet syndrome in perspective.

Authors:  J Damas-Mora; M Skelton-Robinson; F A Jenner
Journal:  Psychol Med       Date:  1982-05       Impact factor: 7.723

4.  Social and psychological characteristics of elderly visually handicapped patients with the Charles Bonnet Syndrome.

Authors:  R J Teunisse; J R Cruysberg; W H Hoefnagels; Y Kuin; A L Verbeek; F G Zitman
Journal:  Compr Psychiatry       Date:  1999 Jul-Aug       Impact factor: 3.735

5.  Charles Bonnet syndrome in leprosy; prevalence and clinical characteristics.

Authors:  N Adachi
Journal:  Acta Psychiatr Scand       Date:  1996-04       Impact factor: 6.392

6.  Visual hallucinations in psychologically normal people: Charles Bonnet's syndrome.

Authors:  R J Teunisse; J R Cruysberg; W H Hoefnagels; A L Verbeek; F G Zitman
Journal:  Lancet       Date:  1996-03-23       Impact factor: 79.321

7.  Visual perceptual disorders resembling the Charles Bonnet syndrome. A study of 434 consecutive patients referred to a psychogeriatric unit.

Authors:  L Norton-Willson; M Munir
Journal:  Fam Pract       Date:  1987-03       Impact factor: 2.267

8.  The Charles Bonnet syndrome: a large prospective study in The Netherlands. A study of the prevalence of the Charles Bonnet syndrome and associated factors in 500 patients attending the University Department of Ophthalmology at Nijmegen.

Authors:  R J Teunisse; J R Cruysberg; A Verbeek; F G Zitman
Journal:  Br J Psychiatry       Date:  1995-02       Impact factor: 9.319

9.  Complex visual hallucinations in partial blindness due to eye disease.

Authors:  N J White
Journal:  Br J Psychiatry       Date:  1980-03       Impact factor: 9.319

Review 10.  [The Charles Bonnet syndrome].

Authors:  K Podoll; M Osterheider; J Noth
Journal:  Fortschr Neurol Psychiatr       Date:  1989-02       Impact factor: 0.752

View more
  4 in total

1.  Dynamic changes in visual acuity as the pathophysiologic mechanism in Charles Bonnet syndrome (visual hallucinations).

Authors:  Colin S H Tan; Bernhard A Sabel
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2005-08-04       Impact factor: 5.270

2.  Charles Bonnet syndrome associated with first attack of MS.

Authors:  Colin S H Tan; Kah Guan Au Eong
Journal:  Jpn J Ophthalmol       Date:  2007 Jan-Feb       Impact factor: 2.447

3.  Charles Bonnet syndrome in cranio-maxillofacial surgery: case report.

Authors:  Thomas Gander; Heinz-Theo Lübbers; Wolfgang Zemann; Christine Jacobsen
Journal:  Oral Maxillofac Surg       Date:  2013-03-05

Review 4.  Hallucinations Experienced by Visually Impaired: Charles Bonnet Syndrome.

Authors:  Linda Pang
Journal:  Optom Vis Sci       Date:  2016-12       Impact factor: 1.973

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.